journal article·2022-03Open access

Polymeric nanoparticles in the diagnosis and treatment of myocardial infarction: Challenges and future prospects

Mia Karam, Duaa Fahs, Batoul Maatouk, Brouna Safi, Ayad A. Jaffa, Rami Mhanna

Abstract

Myocardial infarction (MI) is the leading cause of morbidity and mortality worldwide. Despite extensive efforts to provide early diagnosis and adequate treatment regimens, detection of MI still faces major limitations and pathological MI complications continue to threaten the recovery of survivors. Polymeric nanoparticles (NPs) represent novel noninvasive drug delivery systems for the diagnosis and treatment of MI and subsequent prevention of fatal heart failure. In this review, we cover the recent advances in polymeric NP-based diagnostic and therapeutic approaches for MI and their application as multifunctional theranostic tools. We also discuss the in vivo behavior and toxicity profile of polymeric NPs, their application in noninvasive imaging, passive, and active drug delivery, and use in cardiac regenerative therapy. We conclude with the challenges faced with polymeric nanosystems and suggest future efforts needed for clinical translation.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Cardiac Fibrosis and Remodeling · Coronary Interventions and Diagnostics · Nanoparticles: synthesis and applications

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (100+)

Show source-provided references
1. The pathophysiology of myocardial ischemia and perioperative myocardial infarction10.1053/j.jvca.2019.10.005 ↗
2. Heart disease and stroke statistics--2014 update: a report from the American Heart Association
3. The importance of identification of the myocardial-specific isoenzyme of creatine phosphokinase (MB form) in the diagnosis of acute myocardial infarction10.1161/01.CIR.47.2.263 ↗
4. Medical care costs among patients with established cardiovascular disease
5. Nanomedicine applied to cardiovascular diseases: latest developments10.1177/1753944717692293 ↗
6. Third universal definition of myocardial infarction10.1016/j.jacc.2012.08.001 ↗
7. Joshua Chadwick Jayaraj, et al., Epidemiology of myocardial infarction Intech, (2018), pp. e707102, 10.5772/intechopen.74768.10.5772/intechopen.74768 ↗
8. Universal definition of myocardial infarction10.1093/eurheartj/ehm355 ↗
9. New universal definition of myocardial infarction10.1016/j.gheart.2012.10.005 ↗
10. Third universal definition of myocardial infarction Nat
11. Pathophysiology of myocardial infarction10.1002/j.2040-4603.2015.tb00664.x ↗
12. Systematic characterization of myocardial inflammation, repair, and remodeling in a mouse model of reperfused myocardial infarction10.1369/0022155413493912 ↗
13. Monocytes: protagonists of infarct inflammation and repair after myocardial infarction10.1161/CIRCULATIONAHA.109.916346 ↗
14. Bearing my heart: the role of extracellular matrix on cardiac development, homeostasis, and injury response10.3389/fcell.2020.621644 ↗
15. Enhanced efferocytosis of apoptotic cardiomyocytes through myeloid-epithelial-reproductive tyrosine kinase links acute inflammation resolution to cardiac repair after infarction Circ
16. The biological basis for cardiac repair after myocardial infarction: from inflammation to fibrosis10.1161/CIRCRESAHA.116.303577 ↗
17. Knowledge gaps to understanding cardiac macrophage polarization following myocardial infarction10.1016/j.bbadis.2016.05.013 ↗
18. Regulatory role of dendritic cells in postinfarction healing and left ventricular remodeling10.1161/CIRCULATIONAHA.111.052126 ↗
19. Activation of CD4+ T lymphocytes improves wound healing and survival after experimental myocardial infarction in mice10.1161/CIRCULATIONAHA.111.044164 ↗
20. Fibroblasts in myocardial infarction: a role in inflammation and repair10.1016/j.yjmcc.2013.11.015 ↗
21. The role of alpha-smooth muscle actin in fibroblast-mediated matrix contraction and remodeling Biochim Biophys10.1016/j.bbadis.2016.11.006 ↗
22. The pathogenesis of cardiac fibrosis Cell10.1007/s00018-013-1349-6 ↗
23. Cardiac fibrosis: cell biological mechanisms, molecular pathways and therapeutic opportunities10.1016/j.mam.2018.07.001 ↗
24. A fluorescence immunochromatographic assay using Europium (III) chelate microparticles for rapid, quantitative and sensitive detection of creatine kinase10.1007/s10895-016-1786-3 ↗
25. Improved efficiency and cost reduction in the emergency department by replacing contemporary sensitive with high-sensitivity cardiac troponin immunoassay
26. The utility of troponin measurement to detect myocardial infarction: review of the current findings
27. Biomarkers in acute myocardial infarction: current perspectives10.2147/VHRM.S166157 ↗
28. Monoclonal antibodies against human cardiac troponin I for immunoassays II10.1089/mab.2014.0088 ↗
29. Rapid and sensitive detection of cardiac troponin I for point-of-care tests based on red fluorescent microspheres10.3390/molecules23051102 ↗
30. MR imaging of myocardial infarction10.1148/rg.335125722 ↗
31. Factors associated with false-negative cardiovascular magnetic resonance perfusion studies: a Clinical evaluation of magnetic resonance imaging in coronary artery disease (CE-MARC) substudy10.1002/jmri.25032 ↗
32. Contrast agents for cardiovascular magnetic resonance imaging: an overview10.1039/C7TB01241A ↗
33. MR imaging safety considerations of gadolinium-based contrast agents gadolinium retention and nephrogenic systemic fibrosis magnetic resonance imaging
34. Multicenter evaluation of dynamic three-dimensional magnetic resonance myocardial perfusion imaging for the detection of coronary artery disease defined by fractional flow reserve Circ10.1161/CIRCIMAGING.114.003061 ↗
35. La Grutta · Infarct characterization using CT Cardiovasc Diagn Ther · 2017 · 7 · 171
36. Delayed enhancement cardiac computed tomography for the assessment of myocardial infarction: from bench to bedside10.21037/cdt.2017.03.16 ↗
37. Preventing myocardial infarction: use and limitation of non-invasive imaging modalities10.1093/eurheartj/suaa073 ↗
38. Use of intravenous iodinated contrast media in patients with kidney disease: consensus statements from the
39. Diagnostic accuracy of coronary CT angiography combined with dual-energy myocardial perfusion imaging for detection of myocardial infarction10.3892/etm.2017.4485 ↗
40. Marti-Bonmati · Multimodality imaging techniques Contrast Media Mol Imaging · 2010 · 5 · 18010.1002/cmmi.393 ↗
41. Application of hybrid matrix metalloproteinase-targeted and dynamic (201)Tl single-photon emission computed tomography/computed tomography imaging for evaluation of early post-myocardial infarction remodeling10.1161/CIRCIMAGING.119.009055 ↗
42. Molecular hybrid positron emission tomography/computed tomography imaging of cardiac angiotensin II type 1 receptors10.1016/j.jacc.2012.09.023 ↗
43. PET/MRI early after myocardial infarction: evaluation of viability with late gadolinium enhancement transmurality vs. 18F-FDG uptake
44. Performance of cardiac cadmium-zinc-telluride gamma camera imaging in coronary artery disease: a review from the cardiovascular committee of the European Association of Nuclear Medicine (EANM)10.1007/s00259-016-3467-5 ↗
45. Comparison of clinical non-commercial tools for automated quantification of myocardial blood flow using oxygen-15-labelled water PET/CT10.1093/ehjci/jet177 ↗
46. Measurement of LV volumes and function using oxygen-15 water-gated PET and comparison with CMR imaging10.1016/j.jcmg.2016.01.014 ↗
47. Significance of antiplatelet therapy in emergency myocardial infarction treatment Postepy Kardiol
48. Pharmacokinetics and pharmacodynamics of approved and investigational P2Y12 receptor antagonists10.1007/s40262-020-00864-4 ↗
49. Baker · Cangrelor Hosp Pharm · 2015 · 50 · 92210.1310/hpj5010-922 ↗
50. Antiplatelet therapy for long-term secondary prevention after myocardial infarction10.1001/jamacardio.2016.2110 ↗
51. Glycoprotein IIb/IIIa inhibitors
52. Anticoagulants for secondary prevention after acute myocardial infarction: lessons from the past decade10.1111/fcp.12063 ↗
53. Determining risk factors of bleeding in patients on warfarin treatment10.1155/2014/369084 ↗
54. Warfarin therapy: survey of patients' knowledge of their drug regimen malays
55. Role of apixaban (eliquis) in the treatment and prevention of thromboembolic disease
56. Non-hemorrhage-related adverse effects of rivaroxaban10.5114/amsad.2017.72533 ↗
57. Anticoagulation with direct thrombin inhibitors during extracorporeal membrane oxygenation World
58. Assessing safety of direct thrombin inhibitors, direct factor Xa inhibitors and vitamin K antagonists in patients with atrial fibrillation: a nation-wide propensity score matched cohort from Sweden10.2147/CLEP.S258373 ↗
59. Macrocyclic prodrugs of a selective nonpeptidic direct thrombin inhibitor display high permeability
60. Early intravenous beta-blockers in patients with ST-segment elevation myocardial infarction before primary percutaneous coronary intervention10.1016/j.jacc.2016.03.522 ↗
61. Bisoprolol protects myocardium cells against ischemia/reperfusion injury by attenuating unfolded protein response in rats10.1038/s41598-017-12366-8 ↗
62. An overview on formulation and development of nanoparticulate matrix tablets for beta blockers
63. Systematic review of genuine versus spurious side-effects of beta-blockers in heart failure using placebo control: recommendations for patient information10.1016/j.ijcard.2013.05.068 ↗
64. Treatment with statins in elderly patients
65. Matrix metalloproteinases in myocardial infarction and heart failure progress in molecular biology and
66. Angiotensin converting enzyme inhibitors (ACEI)
67. Application of nanotechnology to improve the therapeutic benefits of statins10.1016/j.drudis.2018.09.023 ↗
68. Statins: pros and cons Med10.1016/j.medcli.2017.11.030 ↗
69. Thrombolytics and myocardial infarction10.1111/j.1755-5922.2010.00239.x ↗
70. Aspect of thrombolytic therapy: a review
71. Percutaneous coronary intervention
72. Role of coronary artery bypass grafting during the acute and subacute phase of ST-elevation myocardial infarction10.1007/BF03091790 ↗
73. Coronary artery bypass graft
74. Mortality pattern and cause of death in a long-term follow-up of patients with STEMI treated with primary PCI Open
75. Modi · 2020
76. Understanding and managing in-stent restenosis: a review of clinical data, from pathogenesis to treatment10.21037/jtd.2016.10.93 ↗
77. Coronary artery bypass graft surgery cost coverage by the Brazilian unified health system (SUS)
78. Atrial fibrillation post cardiac bypass surgery Avicenna
79. Secondary surgical-site infection after coronary artery bypass grafting: a multi-institutional prospective cohort study10.1016/j.jtcvs.2017.10.078 ↗
80. Acute kidney injury after coronary artery bypass grafting and long-term risk of end-stage renal disease10.1161/CIRCULATIONAHA.114.010622 ↗
81. Vitamin D and postoperative delirium after coronary artery bypass grafting: a prospective cohort study10.1053/j.jvca.2020.02.008 ↗
82. Chitosan-modified PLGA nanoparticles for control-released drug delivery polymers
83. Anti-inflammatory/infection PLA nanoparticles labeled with technetium 99m for in vivo imaging10.1007/s11051-017-4037-x ↗
84. DNA-functionalized dye-loaded polymeric nanoparticles: ultrabright FRET platform for amplified detection of10.1021/jacs.8b05840 ↗
85. Therapeutic nanoparticles and their targeted delivery applications10.3390/molecules25092193 ↗
86. Co-delivery of drugs and genes using polymeric nanoparticles for synergistic cancer therapeutic effects advanced
87. Chapter 37 - development of engineered nanoparticles expediting diagnostic and therapeutic applications across blood–brain barrier
88. Multi-responsive hollow nanospheres self-assembly by amphiphilic random copolymer and azobenzene10.1016/j.polymer.2019.04.071 ↗
89. Polymer nanoparticles: preparation techniques and size-control parameters10.1016/j.progpolymsci.2011.01.001 ↗
90. Polymeric nanoparticles for targeted treatment in oncology: current insights
91. Fundamentals of emulsion polymerization10.1021/acs.biomac.0c00769 ↗
92. An overview of pickering emulsions: solid-particle materials, classification, morphology, and applications10.3389/fphar.2017.00287 ↗
93. Effect of process and formulation variables on the preparation of parenteral paclitaxel-loaded biodegradable polymeric nanoparticles: a co-surfactant study
94. Synthesis of monodispersed crosslinked nanoparticles decorated with surface carboxyl groups via soapless emulsion polymerization10.1016/j.colsurfa.2009.05.016 ↗
95. Synthesis of polymer nanoparticles based highly selective membranes by mini-emulsion polymerization for dehydration of 1,4 dioxane and recovery of ethanol from water by pervaporation10.1016/j.memsci.2020.118646 ↗
96. Preparation of polymeric nanomaterials using emulsion polymerization10.1155/2021/1539230 ↗
97. Integration of zwitterionic polymer nanoparticles in interfacial polymerization for ion separation10.1021/acsapm.9b01192 ↗
98. Recent developments and future challenges in controlled radical polymerization: a 2020 update
99. Polymeric nanoparticles: a study on the preparation variables and characterization methods10.1016/j.msec.2017.06.004 ↗
100. Development of a nanoprecipitation method for the entrapment of a very water soluble drug into Eudragit RL nanoparticles10.4103/1735-5362.199041 ↗